Neither juvenile nasopharyngeal angiofibroma (JNA) nor otosclerosis is primarily treated with medications. JNA is a benign but highly vascular tumour that requires surgical removal, often after a procedure called embolization to reduce bleeding during surgery. Otosclerosis, which causes hearing loss due to abnormal bone growth in the middle ear, is mainly managed with surgical treatment such as stapedectomy or stapedotomy or with hearing aids. While certain medications may sometimes be prescribed to slow disease progression in otosclerosis, they are not curative. It is important to consult an ENT specialist for individualised treatment planning and to avoid self-medication, as these conditions require specialised care.

Otosclerosis causing this degree of hearing loss can be managed with hearing amplification using hearing aids or surgically through stapedectomy or stapedotomy to restore hearing. The appropriate treatment is determined by the doctor based on the severity of hearing loss, overall health, and patient preference. Regular audiological follow-up is recommended to monitor progression and treatment outcomes.

Seeking a second opinion from another experienced ENT specialist or a qualified audiologist is appropriate and can provide reassurance regarding the diagnosis. Additional tests, such as audiometry or a high-resolution CT scan of the temporal bone, may be recommended to confirm the presence and extent of otosclerosis, guide treatment decisions, and rule out other possible causes of hearing loss.

The medication commonly prescribed for otosclerosis that contains sodium fluoride is Otoflour. It is typically used to help slow the progression of the condition by stabilizing abnormal bone metabolism in the inner ear, but it does not cure otosclerosis.